CoChat

Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease

Open access
Vanhove, Wiebe, Peeters, Paul M., Staelens, Dominiek, Schraenen, Anica, Van der Goten, Jan, Cleynen, Isabelle, De Schepper, Sebastiaan, Van Lommel, Leentje, Reynaert, Niki L., Schuit, Frans, Van Assche, Gert, Ferrante, Marc, De Hertogh, Gert, Wouters, Emiel F. M., Rutgeerts, Paul, Vermeire, Séverine, Nys, Kris, Arijs, Ingrid · 2015 · Inflammatory Bowel Diseases
Cited by 143

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the gut, partly driven by defects in the innate immune system. Considering the central role of inflammasome signaling in innate immunity, we studied inflammasome components in IBD mucosa. METHODS: Expression of genes encoding inflammasome sensor subunits was investigated in colonic mucosal biopsies from 2 cohorts of patients with IBD and controls. RESULTS: A significant upregulation (>2-fold change in expression, false discovery rate <0.05) of the PYHIN inflammasomes AIM2 and IFI16 in active IBD versus controls was found. Also IFI16 was significantly increased in inactive IBD versus controls. Moreover, responders to anti-tumor necrosis factor therapy showed decreased expression of these inflammasomes although IFI16 remained significantly increased in responders showing endoscopic healing versus controls. AIM2 was mainly expressed in epithelial cells, whereas IFI16 was expressed in both lymphocytes and epithelial cells. Functional activation of predominant AIM2/IFI16-mediated inflammasomes in active IBD colon was shown by the presence of the downstream effectors CASP1 and HMGB-1 in inflamed mucosa. CONCLUSIONS: Our results highlight the importance of PYHIN inflammasome signaling in IBD and also link anti-tumor necrosis factor responsiveness to inflammasome signaling. Together, this points to the potential value of the inflammasome pathway as a new therapeutic target for IBD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mib.0000000000000535

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 143

Metadata

Authors
Vanhove, W., Peeters, P. M., Staelens, D., Schraenen, A., Van der Goten, J., Cleynen, I., De Schepper, S., Van Lommel, L., Reynaert, N. L., Schuit, F., Van Assche, G., Ferrante, M., De Hertogh, G., Wouters, E. F. M., Rutgeerts, P., Vermeire, S., Nys, K., & Arijs, I.
Venue
Inflammatory Bowel Diseases
Published
2015-11
Volume
21
Issue
11
Pages
2673-2682
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2396058978
Cited by
143
References
15
FWCI
4.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1097/mib.0000000000000535
The paper
Vanhove, W., Peeters, P. M., Staelens, D., Schraenen, A., Van der Goten, J., Cleynen, I., De Schepper, S., Van Lommel, L., Reynaert, N. L., Schuit, F., Van Assche, G., Ferrante, M., De Hertogh, G., Wouters, E. F. M., Rutgeerts, P., Vermeire, S., Nys, K., & Arijs, I. (2015). Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.